solute carrier family 22 member 5Genealiases: CDSP · OCTN2
Q-omics provides the consensus-scored SLC22A5 profile across patient tissues and cancer cell-line models. SLC22A5 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, SLC22A5 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, SLC22A5 RNA expression shows 20,485 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight READ, COAD, and UVM as cancer lineages where SLC22A5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC22A5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC22A5 survival associations across molecular data types. SLC22A5 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC22A5 RNA expression–survival associations across cancer types. High SLC22A5 expression shows unfavorable associations in HNSC, LIHC and UVM, but favorable associations in READ, KIRC and UCEC. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify READ as the clearest survival context for SLC22A5 RNA expression.
This table summarizes SLC22A5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC22A5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC22A5 shows lower tumor expression in COAD, KICH and READ and higher tumor expression in KIRC, LIHC and BRCA. The COAD box plot shows higher SLC22A5 RNA expression in normal versus tumor tissue (log2 FC = −1.610, t-test p < 0.001).
This table shows molecular features associated with SLC22A5 in patient tissues and cancer cell lines. In patient samples, SLC22A5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC22A5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
